Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer - Wikidata - wikimedia - TriplyDB

Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer

Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer

http://www.wikidata.org/entity/Q37532636

about

Surgery in the era of the 'omics revolution BRCA1, a 'complex' protein involved in the maintenance of genomic stability Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.Tumor homologous recombination deficiency assays: another step closer to clinical application?A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date.Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance.New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.Biology and Management of Patients With Triple-Negative Breast Cancer.Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells.DNA Damage and Repair Biomarkers of Immunotherapy Response.PICan: An integromics framework for dynamic cancer biomarker discovery.Combining large number of weak biomarkers based on AUC.Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.Danger signals: Chemotherapy enhancers?Rare cancers: the greatest inequality in cancer research and oncology treatment.Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.

P2860

Q26852061-0943A96B-C191-495D-B5B3-348AA2D5905E Q26853262-42B046F9-01DA-4726-A08F-8332FA52551B Q30000323-BED7A0D7-C9E6-44CC-8D7A-19806DE96323 Q33718199-F149B77C-5F37-46DD-96DF-98F9E27D4E94 Q34520145-012FBFB8-7797-4AC2-AEF5-4A0970AFA27F Q34899498-211D3938-F67B-4B25-BC0D-C58DB1AEB696 Q35664732-245AA333-28F4-4BEB-8AB5-3ED7262DCCAD Q36141688-1160372E-4663-4B35-BAA7-5038C9EAF2F3 Q36235523-7C5292E1-339F-41A0-9394-D5793B43D89B Q36685380-E18C412F-C835-4188-9D7F-49EF36C06735 Q36893736-A10A6F32-79D8-42C6-AEE0-B84D65B57F93 Q38744918-B37608C8-090D-4299-AC03-4B0E4CA5F29B Q38756892-A1BCEB65-F50D-4CC6-BE70-C9CABAA9AFD1 Q38788928-52EAA5AC-0E38-409F-B744-B5C1712ABFB9 Q38851459-D0B48B5D-F2D8-4028-96A1-6D5A719BB5E2 Q38893074-D9938386-1A1F-4A3B-A178-E09E982FDFE2 Q38973714-69CFB65A-4F54-4AE7-AEF4-B2B651C32B95 Q39384263-2061FE36-D5F8-43DC-9C6C-813B8144F1DA Q40266748-2258CE0F-1272-492A-A494-9535935FFBFE Q40676243-E24A3388-C099-4D8A-9E45-252D0063226C Q42274807-A7A77266-4576-4A1C-B610-3E703C0728CD Q44857989-2332DB13-792E-4CCF-9AAA-2E5A5A6AF552 Q47659090-6185E3CD-6246-4061-9ABE-EDC01BDFF4E0 Q47684518-659E49B1-871D-4E30-A005-0FA751ABCE7B Q55055759-D88C3C12-5532-4122-AF0A-0934D84E64F0 Q55710290-BABAC53E-A371-4F53-9A4B-4A4896C5B4B3

P2860

Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer

http://www.wikidata.org/entity/Q37532636

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Identification and validation ...... esponse assay in breast cancer

@en

Identification and validation ...... sponse assay in breast cancer.

@nl

type

label

Identification and validation ...... esponse assay in breast cancer

@en

Identification and validation ...... sponse assay in breast cancer.

@nl

prefLabel

Identification and validation ...... esponse assay in breast cancer

@en

Identification and validation ...... sponse assay in breast cancer.

@nl

P1433

Q37532636-2B57F02D-D81A-41D5-ABA4-267A83203548

P1476

Q37532636-C30AEBB4-AE4F-4DEF-B0BB-7AB9DB73B181

P2093

Q37532636-0194F4DC-98E1-47B6-8787-FFDCCF5FF387

Q37532636-023F0A34-86E9-494F-8A2F-2D413D40DE83

Q37532636-19D3DD63-7EEC-4679-A145-BD0C89294408

Q37532636-27B0E302-209F-4789-99A3-208DA741EC69

Q37532636-2C87E11C-A979-4B62-9398-13BCB792D516

Q37532636-32B249D6-ED8F-402E-9C1E-43B3B58A3B6E

Q37532636-3F7E0A5B-3D9E-4127-BC02-6E6A503A2472

Q37532636-4BC061B7-D085-44D8-BA8D-F380F25E8EB9

Q37532636-52962A10-CC79-4055-8EAF-DB12B2975E16

Q37532636-558BA5E3-C99E-479B-81DD-8C03DE672DCF

P2860

Q37532636-15340DEB-0264-4EF6-A2A9-0CF691D6605B

Q37532636-19116CD6-0564-4F0C-9844-37F63F67262D

Q37532636-1AE0050E-1D1B-404F-AE35-003E051E30D7

Q37532636-1CAED618-7185-4936-970F-387B938BFC59

Q37532636-1E6140D9-DA93-4F31-A3FD-F2A08E7972B0

Q37532636-1FDCD89E-7A0C-4187-933F-FD86799E051E

Q37532636-23887541-65A8-464A-B0C9-916AB42A1CD4

Q37532636-34FBD961-6D18-4D6F-9235-7025AF80F0C3

Q37532636-3A2295D5-F432-4060-8E3B-E77019FFE1DD

Q37532636-4D1AEA28-955B-4003-9B6A-4B33A97A9BA8

P304

Q37532636-1C061420-82B3-4031-A289-8F099FBA2595

P31

Q37532636-F0CFDF59-F908-44F7-8860-F21F794112B6

P356

Q37532636-EAB1EF1F-3F6F-4D2B-9E14-F6B60311C0E7

P407

Q37532636-7D04CAA4-5C71-4F2B-9CC3-94735FD9CB60

P433

Q37532636-D903180B-3A9E-45A5-9D7E-06D6C0373252

P478

Q37532636-B016A358-4B6C-4676-8DC4-7538E4A8E671

P50

Q37532636-7EEAB616-6ADA-4E33-B496-ADE32DEF4D09

P577

Q37532636-F8DCB39C-F83D-4E07-B2BB-429E2472B4F7

P5875

Q37532636-87D68692-5F65-4627-8DCA-BB2AB5F87567

P698

Q37532636-14753412-0B05-4FEC-97FA-8C515C4E65E0

P921

Q37532636-61FC350D-5482-4CF6-BA65-4BA0DE77C25F

P932

Q37532636-BD63DEFD-8102-4BB5-9637-934CB0897459

P356

P1433

Journal of the National Cancer Institute

P1476

Identification and validation ...... esponse assay in breast cancer

@en

P2093

Colin R James

http://www.w3.org/2001/XMLSchema#string

D Paul Harkin

http://www.w3.org/2001/XMLSchema#string

David Boyle

http://www.w3.org/2001/XMLSchema#string

Eamonn O'Brien

http://www.w3.org/2001/XMLSchema#string

Fionnuala A McDyer

http://www.w3.org/2001/XMLSchema#string

Gareth Irwin

http://www.w3.org/2001/XMLSchema#string

Jacqueline James

http://www.w3.org/2001/XMLSchema#string

Jennifer E Quinn

http://www.w3.org/2001/XMLSchema#string

Jude M Mulligan

http://www.w3.org/2001/XMLSchema#string

Katherine E Keating

http://www.w3.org/2001/XMLSchema#string

P2860

Susceptibility pathways in Fanconi's anemia and breast cancer

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2

Triple-Negative Breast Cancer

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

Hallmarks of 'BRCAness' in sporadic cancers

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

Generation of a non-small cell lung cancer transcriptome microarray

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

P304

djt335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT335

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Fergus J. Couch

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259630556

http://www.w3.org/2001/XMLSchema#string

P698

24402422

http://www.w3.org/2001/XMLSchema#string

P921

P932

3906990

http://www.w3.org/2001/XMLSchema#string